Abstract: OBJECTIVE: To evaluate the clinical value of combining the thinprip cytologic test (TCT) with HPV-DNA genotyping for detecting cervical cancer in Eastern Guangdong region, China. METHODS: From March 2011-March 2014, 1 681 females were screened for cervical cancer. All patients underwent TCT and HPV-DNA screening, and cervical biopsies were evaluated for confirmation. RESULTS: Among the 1 681 cases, 399 were TCT positive, with the positive rate of 23.7%;533 cases were HPV-DNA positive, with the positive rate of 31.7%. Along with the development of cervical lesions, the positive rate of HPV-DNA was also increased (P<0.05);267 cases were rated positive based on pathological evaluation. And among the TCT positive patients, the consistency between ASCUS, LSIL, HSIL, SCC and positive diagnosis were 46.8%, 59.8%, 96.3% and 100% respectively. The sensitivity (93.5%), specificity (82.8%) and veracity (92.1%) values for TCT in combination with HPV-DNA screening were significantly greater than the results from individual screening assays (P<0.05). CONCLUSION: The combined HPV and TCT tests can significantly increase the accuracy rate of diagnosis for cervical precancerous lesions, therefore the tests can be considered for clinical applications.

Key words: thinprip cytologic test, HPV-DNA typing, cervical cancer screening, clinical value